Research Roundup: What we’re reading this week
In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.
Results of a large-scale Phase III clinical trial of the most clinically advanced malaria vaccine candidate—R TS,S—showed that the vaccine candidate continues to protect young children and infants from clinical malaria up to 18 months after vaccination.
A new analysis of two HIV vaccine trials shows that the investigational vaccines stimulated a critical immune response in infants born to HIV-positive mothers, researchers reported at the AIDS Vaccine 2013 conference in Spain.
Janet Woodcock—head of the US Food and Drug Administration's Center for Drug Evaluation and Research—is retiring in more than a year, but the drug industry is already worrying about who will replace her.
The New York Times reports that the federal government has continued to enroll ill people in clinical trials at the National Institutes of Health since the government shutdown began, but the pace has slowed dramatically.
PATH and China National Biotec Group Co., Ltd., recently announced that a new Japanese encephalitis vaccine has been prequalified by the World Health Organization, paving the way for expanded access to millions of children in Asia at risk of this disease.